Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice.
Wolfgang M BrücklMartin ReckFrank GriesingerHarald SchäferCornelius KortsikTobias GaskaJustyna RawlukStefan KrügerKonrad KokowskiStephan BudweiserJoachim H FickerChristopher HoffmannAndrea SchülerEckart LaackPublished in: Therapeutic advances in medical oncology (2021)
The results support clinical trial data for afatinib in routine clinical practice, including in patients generally excluded from clinical trials. Outcomes were positive in patients with uncommon EGFR mutations and in those with brain metastases. Treatment benefit was also seen in patients receiving a <40 mg afatinib starting dose, supporting patient-tailored dosing.
Keyphrases
- clinical practice
- clinical trial
- epidermal growth factor receptor
- small cell lung cancer
- brain metastases
- end stage renal disease
- tyrosine kinase
- advanced non small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- case report
- peritoneal dialysis
- phase ii
- electronic health record
- study protocol
- smoking cessation
- replacement therapy
- patient reported outcomes
- deep learning